fbpx
X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Unlock Rare Disease Genomics

Improvements in sequencing technology are increasing the ability of scientists to shed light on previously unresolved medical mysteries and enable the development of rare disease diagnostics.

Rare Diseases Need Better Solutions

Although rare diseases are individually rare, collectively they are common, affecting 1 in 2,000 people worldwide with 80% of cases being genetic in origin and >50% of cases remaining unsolved. This is despite many people undergo diagnostic tests using approaches including microarrays, whole exome, or short-read whole genome sequencing.

Highly accurate long-read sequencing, known as HiFi sequencing, provides a higher resolution approach compared to previously used technologies to better understand the genetic causes of rare disease.

The Benefits of HiFi Sequencing for Rare Diseases

With accuracy >99.9% and long read lengths up to 25 kb, HiFi sequencing allows scientists to find causative pathogenic variants and identify novel disease-associated genes with:

  • Best-in-class variant calling for all variant types including single nucleotide variants (SNV), indels, copy number variants (CNVs), and structural variants (SVs)
  • Complete, accurate, and phased assemblies of the human genome— including regions previously inaccessible to other technologies— for accurate typing of genes including HLA and CYP2D6

Spotlight: Children's Mercy Hospital Uses HiFi Sequencing in Genomic Answers for Kids Study

Genomic Answers 4 Kids

Children’s Mercy Kansas City has expanded its investment in PacBio Sequel IIe Systems to scale up whole genome research initiatives focused on rare disease research, and the results are already beginning to add up. Read about their success in resolving the mysteries of rare and inherited disease in children in our newly released customer success story.

 

How HiFi Sequencing Helps Answer Difficult Rare Disease Questions

In the video below, Dr. Emily G. Farrow of Children’s Mercy Kansas City discusses three studies in which PacBio HiFi sequencing was able to explain genetic mysteries where other technologies had failed due to several challenges including phasing of variants, achieving even sequence coverage, and sequencing repetitive regions.

Explore the Range of HiFi Sequencing Applications

Whole Genome Sequencing
Generate reference-quality de novo genome assemblies
Variant Detection
Comprehensively detect all variants in the human genome
Targeted Sequencing
Focus on variation in even the most difficult regions of the genome, and explore our No-Amp method of targeted sequencing
RNA Sequencing
Get a complete view of transcript isoform diversity – no assembly required

Scalable Human Whole Genome HiFi Sequencing for Rare and Inherited Disease Research

Explore our efficient and scalable workflow, developed in collaboration with Children’s Mercy Kansas City, for high-throughput sequencing and comprehensive variant detection to better understand the genetic causes of rare and inherited diseases.


Spotlight: 12 kb Inversion Identified as Causative in Syndromic Intellectual Disability

HiFi sequencing of a trio identifies a pathogenic heterozygous 12 kb de novo inversion that disrupts BRPF1 the gene. SNVs (marked with “*”) show that the inversion occurred on the maternal allele #3. Read more about this study in the blog post.

Mizuguchi, T., et al. (2021) Pathogenic 12-kb copy-neutral inversion in syndromic intellectual disability identified by high-fidelity long-read sequencing. Genomics. 113(1).

Connect with a PacBio scientist to discuss how your rare disease research can benefit from highly accurate long-read sequencing.

Selected Resources